PEPG - NASDAQ

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%

HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$101.28M

EPS-2.1200

P/E Ratio-0.69

Earnings Date08/06/2026

pepg

Net Interest Income

Last Annual Value

4.02M

3-Year CAGR

13%

5-Year CAGR

247%

10-Year CAGR

Adjust for Inflation

PepGen Inc. Competitors Analysis of Net Interest Income

PEPG · NASDAQ

Company	Net Interest Income	CAGR 3Y	CAGR 5Y	CAGR 10Y
PepGen Inc. NASDAQ:PEPG	4.02M	-14.4%	N/A	N/A
Alector, Inc. NASDAQ:ALEC	0.00	N/A	N/A	N/A
Nkarta, Inc. NASDAQ:NKTX	15.49M	3.2%	111.1%	N/A
Applied Therapeutics, Inc. NASDAQ:APLT	3.53M	37.1%	N/A	N/A
Actuate Therapeutics Inc NASDAQ:ACTU	267.46K	-4.7%	N/A	N/A
Alto Neuroscience, Inc. NYSE:ANRO	4.13M	61.6%	360.3%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	0.00	N/A	N/A	N/A
Nuvectis Pharma, Inc. NASDAQ:NVCT	1.13M	21.1%	209.3%	N/A
Instil Bio, Inc. NASDAQ:TIL	-1.97M	N/A	N/A	N/A
Cassava Sciences, Inc. NASDAQ:SAVA	0.00	N/A	N/A	N/A
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	5.53M	N/A	N/A	154.9%

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

HIDDEN

Intrinsic Value

Current Price: $1.4642

Related Guides

Blog Categories

Continue your PEPG research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.